Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate

 Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the
 Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According
                 to Surveyed U.S. Oncologists and Urologists

PR Newswire

EXTON, Pa., March 25, 2013

EXTON, Pa., March 25, 2013 /PRNewswire/ --BioTrends Research Group, one of
the world's leading research and advisory firms for specialized
biopharmaceuticals issues, finds that, despite the 2012 launch of
Medivation/Astellas Pharma's Xtandi (enzalutamide) for the treatment of
docetaxel-pretreated metastatic castrate-resistant prostate cancer (mCRPC),
surveyed oncologists report that Johnson & Johnson/Janssen
Biotech/Janssen-Cilag's Zytiga continues to dominate the second-line mCRPC
setting—although its share dropped marginally from Q3 2012 to Q1 2013. The
patient share of Sanofi's Jevtana showed a marked decline over this time
period as a result of Xtandi's availability, especially in the third line
where Jevtana's patient share in Q1 2013 is half that of its reported share in
Q3 2012. The findings are from the TreatmentTrends^® Prostate Cancer (US) Q1
2013 report, in which 53 urologists and 51 medical oncologists were surveyed
about their current and expected treatment practices for prostate cancer.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

"In the first-line symptomatic mCRPC setting, docetaxel still dominates
treatment according to surveyed oncologists, despite the recent label
extension of Zytiga for chemotherapy-naive mCRPC in December 2012," said
Decision Resources Group Analyst Khurram Nawaz, M.Sc. "Nevertheless, surveyed
oncologists indicate that Zytiga's patient share for first-line symptomatic
mCRPC has almost doubled from Q3 2012 to Q1 2013. Interestingly, both surveyed
urologists and oncologists indicate that Xtandi is also prescribed for
first-line mCRPC patients, although this off-label use remains minimal due to
perceived reimbursement challenges."

Surveyed physicians are most satisfied with Zytiga as a treatment for mCRPC;
Dendreon's Provenge and mitoxantrone have the lowest levels of overall
satisfaction. Satisfaction scores for the efficacy of therapies used to treat
mCRPC are similar in Q1 2013 compared with prior waves of research; however,
satisfaction with Xtandi in Q1 2013 is greater than the level of satisfaction
with Zytiga in Q1 2012.

With respect to emerging therapies, improved efficacy is the most desirable
attribute for emerging therapies in mCRPC, but sustained effects and long-term
safety are also critical. On average, surveyed urologists more than
oncologists prefer oral formulations and therapies that do not require
monitoring. Surveyed physicians are more familiar with Algeta/Bayer
HealthCare's radium-223 and Bristol-Myers Squibb's Yervoy than they are with
other therapies in development for mCRPC. Surveyed physicians rate
radium-223—which has been filed with the FDA and EMA, and granted priority
review by the FDA—as the therapy in which they are most interested.

TreatmentTrends^® Prostate Cancer is a syndicated report designed to provide a
view of the current and future management of prostate cancer based on primary
research fielded with 50 urologists and 50 medical oncologists in the United
States. The report evaluates treatment and diagnosis patterns of the disease
and physician opinions on possible future therapy options. BioTrends Oncology
is also covering the launch of Xtandi and potential launch of radium-223
through its LaunchTrends^® studies.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market
research to pharmaceutical manufacturers competing in clinically evolving,
specialty pharmaceutical markets. For information on BioTrends publications
and research capabilities, please contact us at www.bio-trends.com.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be
trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com

SOURCE BioTrends Research Group

Website: http://www.bio-trends.com
 
Press spacebar to pause and continue. Press esc to stop.